ATE520783T1 - Lentivirale vektoren - Google Patents
Lentivirale vektorenInfo
- Publication number
- ATE520783T1 ATE520783T1 AT97909437T AT97909437T ATE520783T1 AT E520783 T1 ATE520783 T1 AT E520783T1 AT 97909437 T AT97909437 T AT 97909437T AT 97909437 T AT97909437 T AT 97909437T AT E520783 T1 ATE520783 T1 AT E520783T1
- Authority
- AT
- Austria
- Prior art keywords
- lentiviral vectors
- vector particles
- provirus
- letiviruses
- ltr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mushroom Cultivation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621680.9A GB9621680D0 (en) | 1996-10-17 | 1996-10-17 | Lentiviral vectors |
| PCT/GB1997/002858 WO1998017816A1 (en) | 1996-10-17 | 1997-10-17 | Lentiviral vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE520783T1 true ATE520783T1 (de) | 2011-09-15 |
Family
ID=10801598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97909437T ATE520783T1 (de) | 1996-10-17 | 1997-10-17 | Lentivirale vektoren |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6235522B1 (de) |
| EP (1) | EP0939827B1 (de) |
| JP (1) | JP2001502903A (de) |
| KR (1) | KR20000049250A (de) |
| CN (1) | CN1195864C (de) |
| AT (1) | ATE520783T1 (de) |
| AU (1) | AU737801B2 (de) |
| BG (1) | BG103334A (de) |
| CA (1) | CA2268271A1 (de) |
| CZ (1) | CZ137299A3 (de) |
| GB (2) | GB9621680D0 (de) |
| HK (1) | HK1018481A1 (de) |
| HU (1) | HUP0000442A3 (de) |
| IL (1) | IL128564A0 (de) |
| NO (1) | NO991742L (de) |
| NZ (1) | NZ334522A (de) |
| PL (1) | PL332876A1 (de) |
| WO (1) | WO1998017816A1 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924123B2 (en) * | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| AU741747B2 (en) | 1997-05-13 | 2001-12-06 | University Of North Carolina At Chapel Hill, The | Lentivirus-based gene transfer vectors |
| FI112580B (fi) | 1997-06-27 | 2003-12-15 | Nokia Corp | Kutsunsiirron reititys peruspalvelukohtaisesti |
| EP1017797B1 (de) | 1997-09-24 | 2005-06-22 | The Regents Of The University Of California | Nicht-primaten lentivirale vektoren und verpackungssysteme |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| EP1088086A4 (de) | 1998-06-24 | 2003-01-08 | Musc Found For Res Dev | Gewebe-spezifische sowie ziel-rna-spezifische ribozyme |
| US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| WO2000066759A1 (en) | 1999-04-29 | 2000-11-09 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| EP1083230A1 (de) * | 1999-09-10 | 2001-03-14 | Academisch Medisch Centrum Amsterdam | Virale Replikons und von induzierenden Wirkstoffen abhängige Viren |
| AU1013701A (en) | 1999-10-22 | 2001-05-08 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| US6656706B2 (en) | 1999-12-23 | 2003-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes |
| EP1702983A3 (de) | 2000-04-13 | 2007-01-10 | Medical University of South Carolina | Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür |
| AU5810201A (en) | 2000-05-10 | 2001-11-20 | Aventis Pasteur | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
| AU2001263160A1 (en) | 2000-05-19 | 2001-12-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution |
| WO2002034929A2 (en) * | 2000-10-20 | 2002-05-02 | Whitehead Institute For Biomedical Research | Expression vectors and uses thereof |
| US7575924B2 (en) | 2000-11-13 | 2009-08-18 | Research Development Foundation | Methods and compositions relating to improved lentiviral vectors and their applications |
| US6712612B1 (en) | 2000-12-12 | 2004-03-30 | Genecure Llc | Safe and stable retroviral helper cell line and related compositions and methods |
| AU2002307393A1 (en) * | 2001-04-20 | 2002-11-05 | The Salk Institute For Biological Studies | Inducible expression of transfected genes |
| WO2002087341A1 (en) * | 2001-05-01 | 2002-11-07 | Genetix Pharmaceuticals, Inc. | Novel self-inactivating (sin) lentiviral vectors |
| EP1412493B1 (de) | 2001-08-02 | 2011-10-05 | Institut Clayton De La Recherche | Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor-produktionssystemen |
| EP1438075A4 (de) * | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | Verfahren und zusammensetzungen in verbindung mit lentiviralen vektoren mit begrenzter expression und ihre anwendungen |
| JP4598398B2 (ja) | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ （ユーケー） リミテッド | ウイルスベクター |
| US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| CA2484166C (en) * | 2002-04-26 | 2011-11-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
| CN1759182A (zh) * | 2002-11-22 | 2006-04-12 | 克雷顿研究院 | 调节基因的组合物和系统 |
| US20070036721A1 (en) * | 2003-09-23 | 2007-02-15 | Uab Resarch Foundation | Methods and compositions for in vivo inflammation monitoring |
| JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾ｃｅａ／ｂ７ベクター |
| WO2005118809A2 (en) * | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
| US20060292159A1 (en) * | 2005-06-08 | 2006-12-28 | Ranscht Barbara E | Methods for the inhibition of neovascularization and cancer metastasis |
| GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| KR101554678B1 (ko) | 2012-10-19 | 2015-09-21 | 영남대학교 산학협력단 | 식물 바이러스를 이용한 식물체 형질전환을 위한 유전자 전달 시스템 및 이의 용도 |
| RS61387B1 (sr) | 2013-02-15 | 2021-02-26 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| TWI582232B (zh) * | 2013-03-13 | 2017-05-11 | Zhong Li | Microbubbles and methods for their manufacture |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EP3031923A1 (de) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentivirale, vektorbasierte immunogene Zusammensetzung gegen Japanische Enzephalitis |
| AU2017214378B2 (en) | 2016-02-01 | 2023-05-04 | Bioverativ Therapeutics Inc. | Optimized Factor VIII genes |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| TWI773695B (zh) | 2016-10-12 | 2022-08-11 | 美商生物維瑞提夫美國公司 | 抗Ｃ１ｓ抗體及其使用方法 |
| KR102431830B1 (ko) | 2016-11-07 | 2022-08-16 | 주식회사 뉴라클사이언스 | 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법 |
| EP3645039A4 (de) | 2017-06-27 | 2021-05-05 | Neuracle Science Co., Ltd | Verwendung von anti-fam19a5-antikörpern zur behandlung von fibrose |
| US11746149B2 (en) | 2017-06-27 | 2023-09-05 | Neuracle Science Co., Ltd. | Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma |
| KR20220031738A (ko) | 2017-06-27 | 2022-03-11 | 주식회사 뉴라클사이언스 | 암 치료를 위한 항-fam19a5 항체의 용도 |
| CN111315774B (zh) | 2017-06-27 | 2023-12-22 | 纽洛可科学有限公司 | 抗fam19a5抗体及其用途 |
| EP3648776A4 (de) | 2017-07-06 | 2021-04-07 | The Medical College of Wisconsin, Inc. | Neue in-vitro- und in-vivo-anreichungsstrategie gegen lymphozyten aus vektortransduzierten hsc zur behandlung von erkrankungen |
| CN111527105A (zh) | 2017-10-11 | 2020-08-11 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
| WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
| KR20240060864A (ko) | 2018-04-24 | 2024-05-08 | 주식회사 뉴라클사이언스 | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 |
| CN112119091A (zh) | 2018-05-10 | 2020-12-22 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5的抗体及其使用方法 |
| EP3841124A4 (de) | 2018-06-29 | 2022-03-23 | ApitBio, Inc. | Anti-l1cam-antikörper und verwendungen davon |
| CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
| JP2022514465A (ja) | 2018-12-06 | 2022-02-14 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| KR20200071198A (ko) | 2018-12-10 | 2020-06-19 | 네오이뮨텍, 인코퍼레이티드 | Nrf2 발현 조절 기반 T 세포 항암면역치료법 |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| AU2021207586A1 (en) | 2020-01-13 | 2022-07-21 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody |
| EP4093751A1 (de) | 2020-01-22 | 2022-11-30 | Outpace Bio, Inc. | Chimäre polypeptide |
| WO2021151006A2 (en) | 2020-01-22 | 2021-07-29 | Outpace Bio, Inc. | Chimeric polypeptides |
| JP2023512657A (ja) | 2020-02-05 | 2023-03-28 | ワシントン・ユニバーシティ | Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法 |
| EP4171657A1 (de) | 2020-06-24 | 2023-05-03 | Bioverativ Therapeutics Inc. | Verfahren zur entfernung des freien faktors viii aus zubereitungen von lentiviralen vektoren, die zur expression des proteins modifiziert sind |
| WO2022087453A1 (en) | 2020-10-22 | 2022-04-28 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| WO2022093718A1 (en) | 2020-10-26 | 2022-05-05 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
| WO2022094475A1 (en) | 2020-11-02 | 2022-05-05 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
| KR20230104175A (ko) | 2020-11-05 | 2023-07-07 | 네오이뮨텍, 인코퍼레이티드 | Il-7 단백질과 뉴클레오타이드 백신의 조합물을 사용한 종양의 치료 방법 |
| WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
| EP4347826A1 (de) | 2021-06-02 | 2024-04-10 | Lyell Immunopharma, Inc. | Nr4a3-defiziente immunzellen und verwendungen davon |
| IL311725A (en) | 2021-09-30 | 2024-05-01 | Bioverativ Therapeutics Inc | Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity |
| WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
| WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
| EP0588914A1 (de) * | 1991-05-29 | 1994-03-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Eukaryotische expressionsvektoren mit steuerung der rns-prozessierung |
| WO1995030755A1 (fr) * | 1994-05-10 | 1995-11-16 | Hisamitsu Pharmaceutical Co., Inc. | Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production |
| WO1995032300A1 (en) | 1994-05-23 | 1995-11-30 | University Of Medicine & Dentistry Of New Jersey | Selective biological destruction of tumor cells |
| US5693508A (en) * | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| DE69627644T2 (de) * | 1995-03-09 | 2004-02-19 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie |
| GB9510272D0 (en) | 1995-05-22 | 1995-07-19 | Isis Innovation | Retroviral vectors |
| WO1997048277A1 (en) * | 1996-06-20 | 1997-12-24 | The Salk Institute For Biological Studies | Modular assembly retroviral vectors and uses thereof |
-
1996
- 1996-10-17 GB GBGB9621680.9A patent/GB9621680D0/en active Pending
-
1997
- 1997-10-17 CA CA002268271A patent/CA2268271A1/en not_active Abandoned
- 1997-10-17 CN CNB971988838A patent/CN1195864C/zh not_active Expired - Lifetime
- 1997-10-17 JP JP10519087A patent/JP2001502903A/ja not_active Ceased
- 1997-10-17 HU HU0000442A patent/HUP0000442A3/hu unknown
- 1997-10-17 CZ CZ991372A patent/CZ137299A3/cs unknown
- 1997-10-17 EP EP97909437A patent/EP0939827B1/de not_active Expired - Lifetime
- 1997-10-17 US US09/284,011 patent/US6235522B1/en not_active Expired - Lifetime
- 1997-10-17 PL PL97332876A patent/PL332876A1/xx unknown
- 1997-10-17 GB GB9903117A patent/GB2331522B/en not_active Expired - Lifetime
- 1997-10-17 NZ NZ334522A patent/NZ334522A/en not_active IP Right Cessation
- 1997-10-17 WO PCT/GB1997/002858 patent/WO1998017816A1/en not_active Application Discontinuation
- 1997-10-17 AU AU47123/97A patent/AU737801B2/en not_active Expired
- 1997-10-17 IL IL12856497A patent/IL128564A0/xx unknown
- 1997-10-17 AT AT97909437T patent/ATE520783T1/de not_active IP Right Cessation
- 1997-10-17 KR KR1019990703355A patent/KR20000049250A/ko not_active Application Discontinuation
-
1999
- 1999-04-13 NO NO991742A patent/NO991742L/no not_active Application Discontinuation
- 1999-04-14 BG BG103334A patent/BG103334A/xx unknown
- 1999-08-17 HK HK99103561A patent/HK1018481A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU4712397A (en) | 1998-05-15 |
| CA2268271A1 (en) | 1998-04-30 |
| JP2001502903A (ja) | 2001-03-06 |
| CN1234075A (zh) | 1999-11-03 |
| GB9903117D0 (en) | 1999-04-07 |
| HUP0000442A3 (en) | 2001-09-28 |
| KR20000049250A (ko) | 2000-07-25 |
| GB2331522B (en) | 2001-05-23 |
| AU737801B2 (en) | 2001-08-30 |
| BG103334A (en) | 2000-06-30 |
| CZ137299A3 (cs) | 1999-07-14 |
| EP0939827A1 (de) | 1999-09-08 |
| GB2331522A (en) | 1999-05-26 |
| US6235522B1 (en) | 2001-05-22 |
| NO991742D0 (no) | 1999-04-13 |
| IL128564A0 (en) | 2000-01-31 |
| NO991742L (no) | 1999-04-13 |
| CN1195864C (zh) | 2005-04-06 |
| GB9621680D0 (en) | 1996-12-11 |
| NZ334522A (en) | 2001-11-30 |
| HUP0000442A2 (hu) | 2000-06-28 |
| PL332876A1 (en) | 1999-10-25 |
| EP0939827B1 (de) | 2011-08-17 |
| WO1998017816A1 (en) | 1998-04-30 |
| HK1018481A1 (en) | 1999-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE520783T1 (de) | Lentivirale vektoren | |
| DE69636581D1 (de) | Retrovirale Vektoren | |
| DE69703974D1 (de) | Retrovirale vektoren | |
| EP0702716A4 (de) | Gentherapy bei hiv-infektion und aids mit hilfe von ribozymen | |
| CA2311641A1 (en) | Pseudo-type retroviral vectors with modifiable surface capsid proteins | |
| DE69534948D1 (de) | Retrovirale vektoren zur expression in embryonalen zellen | |
| PT975783E (pt) | "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas" | |
| NO983375D0 (no) | Retroviral vektor og anvendelse derav i genterapi | |
| ATE406452T1 (de) | Retrovirale vektoren | |
| DK631387A (da) | Virusvektor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |